CMS has continued refining pathways designed to shorten the gap between FDA breakthrough device designation and Medicare coverage determination, a gap that historically left facilities in an awkward position — able to purchase and use a clinically promising new device, but without clear reimbursement certainty for a meaningful stretch of time after market clearance.
Why the Timeline Gap Matters to Procurement
A facility purchasing capital equipment or committing to a new device category needs reasonable confidence that reimbursement will support the investment. When coverage determinations lagged years behind FDA clearance, procurement teams often delayed adoption of genuinely valuable new technology simply to avoid financial exposure during the coverage gap — a caution that faster pathways are intended to reduce.
What's Changed Under Expanded Rapid Pathways
- Shorter formal review timelines for devices carrying breakthrough designation, with defined statutory or regulatory deadlines rather than open-ended review
- Increased use of coverage with evidence development arrangements, allowing conditional coverage while additional real-world data is collected
- Earlier and more structured manufacturer engagement with CMS during the FDA review process itself, rather than coverage discussions starting only after clearance
What Procurement Teams Should Do
Facilities evaluating breakthrough-designated devices should engage finance early to model both the covered and uncovered adoption scenarios, since even accelerated pathways still carry some residual timeline uncertainty. Building that scenario planning into the capital request process avoids the whiplash of adopting a device only to face an unexpected reimbursement gap.
Facilities evaluating new device categories can review Healix Medical Supply's diagnostic equipment catalog.
